Lexeo Therapeutics, Inc.
LXEO
$8.66
$0.344.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 22.30% | 20.07% | -25.97% | 12.09% | -38.85% |
| Total Depreciation and Amortization | 3.92% | 1.80% | -3.84% | 2.36% | 2.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,051.23% | -107.68% | 6.46% | -8.07% | 33.17% |
| Change in Net Operating Assets | -832.51% | -119.93% | 205.04% | -186.77% | 427.30% |
| Cash from Operations | -8.55% | -25.34% | 23.34% | -59.08% | 11.64% |
| Capital Expenditure | -167.59% | -- | -- | 100.00% | 61.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 190.36% | -350.42% | 116.67% | -- | 100.00% |
| Cash from Investing | 189.37% | -351.12% | 116.67% | -112,650.60% | 61.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 31.97% | 23.27% | -37.07% | -4.50% | -50.00% |
| Issuance of Common Stock | -99.83% | 46,958.24% | -97.31% | 16,082.05% | -99.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | 100.00% |
| Cash from Financing | -99.93% | 663,172.73% | 111.34% | -34.72% | -124.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.00% | 207.57% | 95.00% | -579.28% | 10.55% |